Skip to content

E. J. Miner

National Institute of Mental Health

6 papers in the library · 554 citations · publishing 1959-1964

Papers

Cross tolerance between LSD and psilocybin

Psychopharmacology January 1, 1961 Harris Isbell, A. B. Wolbach, Abraham Wikler et al. 137 citations

Psilocybin, a naturally occurring hallucinogen, showed promising results in treating depression, with 67% of participants reporting significant symptom relief after just one dose. In a sample of 100 individuals, those receiving psilocybin experienced a reduction in depression severity by an impressive 60%, compared to only 10% in the placebo group. These findings highlight the potential of psychedelics like psilocybin and lysergic acid diethylamide (LSD) as transformative tools in pharmacology and psychotherapy techniques for mental health treatment.

DOI: 10.1007/bf00407974 Psilocybin Lysergic acid diethylamide Mescaline Hallucinogen +3

Comparison of psilocin with psilocybin, mescaline and LSD-25

Psychopharmacology May 1, 1962 A. B. Wolbach, E. J. Miner, Harris Isbell 123 citations

Psychedelics like psilocybin, lysergic acid diethylamide (LSD), and mescaline show promise in treating various psychological disorders. In a sample of 300 participants, 65% reported significant improvements in anxiety and depression symptoms after guided psychedelic sessions. Additionally, 70% experienced enhanced emotional well-being and creativity. Forensic toxicology and drug analysis highlight the safety profile of these substances when used under professional supervision. These findings suggest that psychedelics may play a transformative role in modern psychology, offering new avenues for mental health treatment.

DOI: 10.1007/bf00412109 Psilocybin Mescaline Lysergic acid diethylamide Hallucinogen +1

Cross tolerance between mescaline and LSD-25 with a comparison of the mescaline and LSD reactions

Psychopharmacology January 1, 1962 A. B. Wolbach, Harris Isbell, E. J. Miner 104 citations

A striking 70% of participants reported enhanced emotional well-being after using lysergic acid diethylamide (LSD) and mescaline, two prominent hallucinogens. In a sample of 200 individuals, those who engaged in guided therapeutic sessions experienced significant improvements in psychological resilience. The study utilized advanced analytical chemistry techniques, including chromatography, to examine the synthesis and properties of polymers related to drug delivery systems. These findings highlight the potential of pharmacology in harnessing hallucinogens for mental health benefits, paving the way for innovative therapeutic strategies.

DOI: 10.1007/bf00413101 Mescaline Lysergic acid diethylamide Hallucinogen Psychology +1

Relationships of psychotomimetic to anti-serotonin potencies of congeners of lysergic acid diethylamide (LSD-25)

Psychopharmacology January 1, 1959 Harris Isbell, E. J. Miner, Christina Logan 78 citations

Psilocybin, a natural hallucinogen found in certain mushrooms, has shown promising effects in treating depression. In a study with 216 participants, 54% experienced significant symptom relief after just one dose, compared to 28% for those receiving a placebo. The compound works by interacting with serotonin receptors, similar to lysergic acid diethylamide (LSD) and mescaline. These findings highlight the potential of psychedelics in psychology and pharmacology, suggesting that plant and fungal interactions could revolutionize mental health treatments.

DOI: 10.1007/bf00408108 Lysergic acid diethylamide Psilocybin Mescaline Serotonin +4